Healthcare / Drug Manufacturers - Specialty & GenericBSE
$521.35
-2.70 (-0.52%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 20%
FCF escenarios
weak_data · normalized FCF $1.9B · quality 43.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
51/100
C
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$79.8B
P/E
31.3x
↑EV/EBITDA
12.3x
↓ROE
7.7%
↑Gross Margin
42.3%
↓Debt/Equity
0.05
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2023–2026 · 3 años de histórico normalizado
Revenue CAGR
+7.9%
FCF CAGR
—
FCF margin
21.8%
FCF / Net income
3.73x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $43.59B · net income $2.55B · FCF $9.51B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $43.59B | $43.59B | $41.18B | $40.20B | $34.75B |
| Net Income | $2.55B | $2.55B | $3.38B | $-40.4M | $948.5M |
| EBITDA | $6.31B | $6.31B | $5.33B | $1.31B | $3.09B |
| EPS | — | — | 22.60 | -0.28 | 6.03 |
| Gross Margin | 42.3% | 42.3% | 40.9% | 35.8% | 33.6% |
| Operating Margin | 8.4% | 8.4% | 7.5% | 9.0% | 5.5% |
| Net Margin | 5.9% | 5.9% | 8.2% | -0.1% | 2.7% |
| Balance Sheet | |||||
| Debt/Equity | 0.05 | 0.05 | 0.03 | 0.80 | 0.86 |
| Current Ratio | 3.25 | 3.25 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $9.51B | $9.51B | $1.93B | $1.87B | $-1.52B |
| Returns | |||||
| ROE | 7.7% | 7.7% | 11.1% | -0.6% | 13.2% |
| Valuation | |||||
| P/E | 31.29 | 31.29 | 19.85 | — | — |
| EV/EBITDA | 12.29 | 12.29 | 12.56 | — | — |
| P/B | 2.41 | 2.41 | 2.20 | — | — |
| Growth & Yield | |||||
| Revenue Growth | 5.8% | 5.8% | 2.4% | 15.7% | — |
| EPS Growth | — | — | 8171.4% | -104.6% | — |
| Dividend Yield | 0.2% | 0.2% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-10.2%
Start / end P/E
n/dx → n/dx
EPS bridge
22.60 → n/d
Residual
-10.4%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.